Skip to main content
. Author manuscript; available in PMC: 2012 Dec 15.
Published in final edited form as: Clin Cancer Res. 2011 Oct 28;17(24):7634–7644. doi: 10.1158/1078-0432.CCR-11-1677

Figure 1.

Figure 1

Schema of pharmacodynamic and pharmacokinetics time points. Patients were administered sunitinib 50 mg daily on the intermittently dosed 4/2 schedule (top) or 2/1 schedule (bottom). FLT PET/CT images were performed at baseline, peak sunitinib exposure, and during sunitinib withdrawal as indicated by the wide arrows. FLT, 18F-Fluorothymidine. PET, positron emission tomography. CT, computed tomography. VEGF, vascular endothelial growth factor. PK, pharmacokinetics. w, week.